Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2026
Reporting Period: Second Quarter ended June 30, 2026
Business Update: The Company issued a press release announcing financial results for the quarter and provided an update on recent business developments.
Key Financial Metrics
The provided filing text serves as a cover document referencing attached exhibits (Exhibit 99.1 and 99.2) for detailed data. The text itself does not provide clear values for the following metrics:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not contain specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The Company provided an update on recent developments in its business, the specifics of which are contained in the attached press release and investor presentation.
Regulation FD Disclosure: The filing includes an investor presentation (Exhibit 99.2) furnished in connection with meetings with institutional investors and analysts. The Company notes this information may be amended or updated in future filings.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this Form 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q2 2026 revenue, net loss, and cash burn figures.
- Examine Exhibit 99.2 (Investor Presentation) for detailed business updates and strategic developments.
- Verify the Company's liquidity runway and cash position as of June 30, 2026, which are not stated in this summary text.
- Check for any forward-looking guidance or updated financial projections included in the supplemental materials.